As LMP1 and EBNA2 are known to modulate the expression of PD-L1 and other immune checkpoint regulators, the drug-induced expression of these proteins could potentially upregulate PD-L1 expression in lymphomas with low PD-L1 expression, making them more vulnerable to ICIs. This evidence concerns the gene PDLIM7 and lymphoma.